Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
The advia centaur multi-diluent (md1) is not meeting the on board stability claims of 28 days as stated in the ifu when used with the advia centaur bnp or the advia centaur tsh-3 ultra assays for automated sample dilutions with the advia centaur or advia centaur xp systems.